Amplia Appoints Brett Carter as Non-Executive Director
Amplia Therapeutics Limited has appointed Brett Carter to its board of directors, effective July 6, 2026. The company highlighted Mr. Carter's extensive experience in pharmaceutical transactions and drug development, particularly relevant for the advancement of Amplia’s lead drug narmafotinib.